Daneng Li - Researcher Profile | RDL Research Database

Publications

3 shown

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in...

2018 The Lancet Oncology 2448 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng , Shukui Qin , Masafumi Ikeda +16 more

2021 Journal of Hepatology 1397 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 10,309
Institution: Beckman Research Institute

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-5330-7522

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.